Company summary
IP Group is an investment company specialising in science and technology businesses emerging from universities and research institutions. It provides capital and support to companies in life sciences, deep technology and cleantech.
← Back to the 350
IPO
IP Group
Financial Services
- Index
- FTSE 250
- ISIN
- Not specified
- Book status
- 2026 edition — current
Key activities
Early- and growth-stage investment, portfolio development, university partnerships, company formation, follow-on funding and realisation of investments through trade sales, licensing and public markets.
Key markets
Primarily UK science and technology, with growing international partnerships and exposure to healthcare, biotechnology, deep tech, artificial intelligence and clean energy.
Key drivers
Portfolio-company funding rounds, clinical and technical milestones, successful exits, licensing income, private-market valuations, new fund partnerships and cash returns from mature investments.
Key risks
High failure rates in early-stage companies, illiquidity, valuation uncertainty, long development times, clinical and regulatory failure, funding-market weakness and concentration in individual breakthrough assets.
Recent Developments
17 March 2026: annual results showed NAV per share up 13% to 110.4p. The group recognised £128.2m of discounted future royalty and milestone income following Pfizer's acquisition of Metsera and completed a £75m share buyback.
Dividend notes
IP Group does not currently rely on a regular dividend programme. Shareholder returns have instead centred on share buybacks and realised investment proceeds; no routine 2026 ex-dividend date had been published by 14 August.
The complete 350 Trade Book — 350 leading UK-listed companies, presented in one consistent working reference.